These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20097563)

  • 1. Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1388-94. PubMed ID: 20097563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6148-56. PubMed ID: 19796941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4657-63. PubMed ID: 19604694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.
    Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Harris PK; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
    J Med Chem; 2010 Mar; 53(5):2010-37. PubMed ID: 20141147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of a new series of PAR1 antagonists.
    Planty B; Pujol C; Lamothe M; Maraval C; Horn C; Le Grand B; Perez M
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1735-9. PubMed ID: 20137929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y1 receptor antagonists as novel antithrombotic agents.
    Pfefferkorn JA; Choi C; Winters T; Kennedy R; Chi L; Perrin LA; Lu G; Ping YW; McClanahan T; Schroeder R; Leininger MT; Geyer A; Schefzick S; Atherton J
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3338-43. PubMed ID: 18445527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.
    Kortum SW; Lachance RM; Schweitzer BA; Yalamanchili G; Rahman H; Ennis MD; Huff RM; TenBrink RE
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5919-23. PubMed ID: 19748783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist.
    Ito S; Satoh A; Nagatomi Y; Hirata Y; Suzuki G; Kimura T; Satow A; Maehara S; Hikichi H; Hata M; Kawamoto H; Ohta H
    Bioorg Med Chem; 2008 Nov; 16(22):9817-29. PubMed ID: 18849168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
    Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
    J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.
    Shao Y; Anilkumar GN; Carroll CD; Dong G; Hall JW; Hobbs DW; Jiang Y; Jenh CH; Kim SH; Kozlowski JA; McGuinness BF; Rosenblum SB; Schulman I; Shih NY; Shu Y; Wong MK; Yu W; Zawacki LG; Zeng Q
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1527-31. PubMed ID: 21277198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors.
    Crepaldi P; Cacciari B; Bonache MC; Spalluto G; Varani K; Borea PA; Kügelgen Iv; Hoffmann K; Pugliano M; Razzari C; Cattaneo M
    Bioorg Med Chem; 2009 Jul; 17(13):4612-21. PubMed ID: 19464902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.
    Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Hase Y; Uchida I; Aisaka K; Katoh S; Cho H
    J Med Chem; 2005 May; 48(10):3586-604. PubMed ID: 15887966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.
    Chackalamannil S; Xia Y; Greenlee WJ; Clasby M; Doller D; Tsai H; Asberom T; Czarniecki M; Ahn HS; Boykow G; Foster C; Agans-Fantuzzi J; Bryant M; Lau J; Chintala M
    J Med Chem; 2005 Sep; 48(19):5884-7. PubMed ID: 16161991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
    Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors.
    Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M
    J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations.
    Giordanetto F; Bach P; Zetterberg F; Antonsson T; Bylund R; Johansson J; Sellén M; Brown D; Hideståhl L; Berntsson P; Hovdal D; Zachrisson H; Björkman JA; van Giezen JJ
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2963-8. PubMed ID: 24835983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.